Kemin Biologics and ilender jointly launch vaccine for avian influenza

The high degree of homology with local strains makes MEFLUVAC™ H5 PLUS 8 the vaccine of choice

Kemin Industries will launch the MEFLUVAC H5 PLUS 8 vaccine in partnership with ilender in Latin America to assist in building immunity against the highly pathogenic Avian Influenza.

Kemin Biologics, the global veterinary vaccine division of Kemin, will debut the new vaccine in Peru at the event and roadshow starting on October 30 in the Peruvian cities of Lima, Trujillo and Chincha. At this event, policy and distribution stakeholders, along with customers from the poultry meat and layer industries, will gather to discuss vaccinology and risk management programs. The industry leaders will focus on the importance of addressing major pathogens that compromise animal performance and food security for the growing population.

“We are excited to introduce our technology and best practices to empower the poultry industry in Peru and Latin America to mitigate the growing threat of highly pathogenic Avian Influenza,” said Dr Ricardo Neto, Technical Service Manager, Kemin Biologics. “The high degree of homology with local strains makes MEFLUVAC™ H5 PLUS 8 the vaccine of choice.”

The high degree of homology with local